Home / First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (Pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC)
Necchi A. 1,
Bandini M. 2,
Gallina A. 2,
Bianchi M. 2,
Raggi D. 1,
Fare' E. 1,
Messina A. 1,
Chung J. 3,
Ali S. 3,
Ross J. 3,
Anichini A. 1,
Colecchia M. 1,
Gandaglia G. 2,
Fossati N. 2,
Scuderi S. 2,
Pederzoli F. 2,
Salonia A. 2,
Colombo R. 2,
Briganti A. 2,
Montorsi F. 2
1
Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy 2
Urological Research Institute (URI), IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy 3
Foundation Medicine, Cambridge, United States of America
